Bipolar depression: Specific treatments

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL. 18, 1998, Pages 30-36

  Potter, William Z ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; AMFEBUTAMONE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOZAPINE; IDAZOXAN; LAMOTRIGINE; MIANSERIN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; SEROTONIN UPTAKE INHIBITOR; VALPROIC ACID; VENLAFAXINE; YOHIMBINE;

ANGER; ANXIETY; BIPOLAR DEPRESSION; CONFERENCE PAPER; DRUG MECHANISM; DRUG SAFETY; HUMAN; HYPERSOMNIA; MAJOR DEPRESSION; MANIA; PRIORITY JOURNAL; TREATMENT INDICATION;

EID: 0031793438     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (55)

1. Henry ME, Potter WZ. Manic-depressive illness: diagnostic issues. Rev Contemp Pharmacother 1995;6:547-555
2. Goodwin FK, Jamison KR. Manic-Depressive Illness. New York, NY: Oxford University Press; 1990
3. Winokur G, Clayton PJ, Reich T. Manic Depressive Illness. St. Louis, Mo: CV Mosby; 1969
4. Kraepelin E. Manic-Depressive Insanity and Paranoia. Baneby RM, trans. Robertson GM, ed. Edinburgh, Scotland: E & S Livingstone; 1921
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
6. Himmelhoch JM, Mulla D, Neil JF, et al. Incidence and significance of mixed affective states in a bipolar population. Arch Gen Psychiatry 1976; 33:1062-1066
7. Secunda SK, Katz MM, Swann A, et al. Mania: diagnosis, state measurement, and prediction of treatment response. J Affect Disord 1985;8: 113-121
8. Post RM, Rubinow DR, Uhde TW, et al. Dysphoric mania: clinical and biological correlates. Arch Gen Psychiatry 1989;46:353-358
9. Akiskal HS. The prevalent clinical spectrum of bipolar disorders: beyond DSM-IV. J Clin Psychopharmacol 1996;16(suppl 1):4S-14S
10. Suppes T, Calabrese JR, Mitchell PB, et al. Algorithms for the treatment of bipolar, manic-depressive illness. Psychopharmacol Bull 1995;31(3): 469-474
11. Prien RF, Caffey EM Jr, Klett CJ. Prophylactic efficacy of lithium carbonate in manic-depressive illness. Arch Gen Psychiatry 1973;28:337-341
12. Prien RF, Kupfer DJ, Mansky PA, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders: report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and lithium carbonate-imipramine combination. Arch Gen Psychiatry 1984;41: 1096-1104
13. Keller MB, Lavori PW, Coryell W, et al. Differential outcome of pure manic, mixed/cycling, and pure depressive episodes in patients with bipolar illness. JAMA 1986;255:3138-3142
14. Maj M, Priozzi R, Kemali D. Long-term outcome of lithium prophylaxis in patients initially classified as complete responders. Psychopharmacology 1989;98:535-538
15. Prien RF, Potter WZ. NIMH workshop report on the treatment of bipolar disorder. Psychopharmacol Bull 1990;26:409-427
16. Wehr TA, Goodwin FK. Rapid cycling in manic-depressives induced by tricyclic antidepressants. Arch Gen Psychiatry 1979;36:555-559
17. Wehr TA, Goodwin FK. Can antidepressants cause mania and worsen the course of affective illness? Am J Psychiatry 1987;144:1403-1411
18. Quitkin FM, Kane J, Rifkin A, et al. Prophylactic lithium carbonate with and without imipramine for bipolar I patients. Arch Gen Psychiatry 1981; 38:902-907
19. Altshuler LL, Post RM, Leverich GS, et al. Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry 1995;152: 1130-1138
20. Kupfer DJ, Carpenter LL, Frank E. Possible role of antidepressants in precipitating mania and hypomania in recurrent depression. Am J Psychiatry 1988;145:804-808
21. Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994;164:549-550
22. Himmelhoch JM, Detre T, Kupfer DJ, et al. Treatment of previously intractable depression with tranylcypromine and lithium. J Nerv Ment Dis 1972; 155:216-220
23. Himmelhoch JM, Thase ME, Mallinger AG, et al. Tranylcypromine vs imipramine in anergic bipolar depression. Am J Psychiatry 1991;148: 910-916
24. Thase ME, Mallinger AG, McKnight D, et al. Treatment of imipramine-resistant recurrent depression, IV: A double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry 1992;149: 195-198
25. Potter WZ, Murphy DL, Wehr TA, et al. Clorgyline: a new treatment for refractory rapid cycling patients? Arch Gen Psychiatry 1982;39:505-510
26. Quitkin FM, McGrath P, Liebowitz MR, et al. Monoamine oxidase inhibitors in bipolar endogenous depressives. J Clin Psychopharmacol 1981;1: 70-74
27. Nolen WA, van de Putte JJ, Dijken WA. Treatment strategy in depression, II: MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine. Acta Psychiatr Scand 1988;78: 676-683
28. Gelenberg AJ, Hopkins HS. Report on the efficacy of treatment for bipolar disorder. Psychopharmacol Bull 1994;29:447-456
29. Watanabe S, Ishino H, Otsuki S. Double-blind comparison of lithium carbonate and imipramine in treatment of depression. Arch Gen Psychiatry 1975;32:659-668
30. Worrall EP, Moody JP, Peet M, et al. Controlled studies of the acute antidepressant effects of lithium. Br J Psychiatry 1979;135:255-262
31. Fieve RR, Platman SR, Plutchik RR. The use of lithium in affective disorders, I: acute endogenous depression. Am J Psychiatry 1968;125:487-491
32. Sachs GS. Bipolar mood disorder: practical strategies for acute and maintenance phase treatment. J Clin Psychopharmacol 1996;16(suppl 1): 32S-47S
33. Cohn JB, Collins G, Ashbrook E, et al. A comparison of fluoxetine, imipramine, and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 1989;4:313-322
34. Goodnick P, Extein I. Bupropion and fluoxetine in depressive subtypes. Ann Clin Psychiatry 1989;1:119-122
35. Haykal RF, Akiskal HS. Bupropion as a promising approach to rapid cycling bipolar II patients. J Clin Psychiatry 1990;51:450-455
36. Sachs GS, Lafer B, Stoll AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994;55:391-393
37. Suppes T, Baldessarini RJ, Faedda GL, et al. Risk of recurrence following discontinuation of lithium treatment of bipolar disorder. Arch Gen Psychiatry 1991;48:1082-1088
38. Gelenburg AJ, Kane JN, Keller MB, et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorders. N Engl J Med 1989;321:1489-1493
39. Prien RF, Himmelhoch JM, Kupfer DJ. Treatment of mixed mania. J Affect Disord 1988;15:9-15
40. Dardennes R, Even C, Bange F, et al. Comparison of carbamazepine and lithium in the prophylaxes of bipolar disorders: a meta-analysis. British Journal of Psychiatry 1995;166:378-381
41. Post RM, Uhde TW, Ballenger JC, et al. Prophylactic efficacy of carbamazepine in manic-depressive illness. Am J Psychiatry 1983;140:1602-1604
42. Denicoff KD, Blake DK, Smith-Jackson EE, et al. Morbidity in treated bipolar disorder: a one-year prospective study using daily life chart ratings. Depression 1994;2:95-104
43. Post RM, Denicoff KD, Frye MA, et al. Re-evaluating carbamazepine prophylaxis in bipolar disorder. Br J Psychiatry 1997;170:202-204
44. Bowden CL, Brugger AM, Swann AC, et al., for the Depakote Mania Study Group. Efficacy or divalproex vs. lithium, placebo in the treatment of mania. JAMA 1994;271:918-924
45. McElroy SL, Keck PE. Treatment guidelines for valproate in bipolar and schizoaffective disorders. Can J Psychiatry 1993;38(suppl 3):S62-S66
46. Calabrese J, Bowden C, McElroy S, et al. Lamictal monotherapy in the treatment of bipolar disorder. Presented at the 10th European College of Neuropharmacology Congress. Sept. 13-17, 1997; Vienna, Austria P. 1.133
47. 2 antagonist and effective sustained antidepressant in two bipolar depressed patients. Arch Gen Psychiatry 1989;46:958-959
48. 2-adrenoceptor antagonists in volunteers and depressed patients. In: Montgomery SA, Corn TH, eds. Psychopharmacology of Depression: British Association for Psychopharmacology Monograph, No. 13. New York, NY: Oxford University Press: 1994:102-128
49. 2-adrenergic receptors: implications for depression. Crit Rev Neurobiol 1994;9:29-66
50. Charney DS, Price LH, Heninger GR. Desipramine-yohimbine combination treatment for refractory depression. Arch Gen Psychiatry 1986;45: 1155-1161
51. McElroy SL, Dessain EC, Pope HG Jr, et al. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 1991;52:411-414
52. deBoer T, Maura G, Raiteri M, et al. Neurochemical and autonomie pharmacological profiles of the 6-AZA-analogue of mianserin, ORG 3770 and its enantiomers. Neuropharmacology 1988;27:399-408
53. Post RM, Roy-Byrne PP, Uhde TW. Graphic representation of the life course of illness in patients with affective disorder. Am J Psychiatry 1988; 145:844-848
54. Ferris RM, Cooper BR. Mechanism of antidepressant activity of bupropion. J Clin Psychiatry Monograph 1993;11:2-14
55. Burrows GD, Kremer CME. Mirtazapine: clinical advantages in the treatment of depression. J Clin Psychopharmacol 1997;17(2, suppl 1):34S-39S